03 September 2010
Keywords: Biogen Idec, Icahn, Board members
Article | 29 January 2010
US biopharmaceutical firm Biogen Idec says it has received notice from Icahn Partners and certain of its affiliates of their intention to nominate three individuals to its board of directors.
The three nominees - basically proposed by billionaire Carl Icahn in his third proxy fight with Biogen – are: Eric Rowinsky, a former chief medical officer of ImClone Systems ( company acquired by Eli Lilly in 2008 for nearly $6 billion); Thomas Deuel, a former board member at ImClone; and Richard Young, a researcher at the Massachusetts Institute of Technology. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.